Haisco Pharmaceutical Group stock
Price history
−7.41% over the period1 year: from ¥56.68 (November 20, 2025) to ¥52.48 (November 20, 2026), −7.41%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | ¥52.48 |
| October 30, 2026 | ¥54.82 |
| September 30, 2026 | ¥62.18 |
| August 31, 2026 | ¥66.81 |
| July 31, 2026 | ¥62.38 |
| June 30, 2026 | ¥66.34 |
| May 29, 2026 | ¥51.57 |
| April 30, 2026 | ¥58.53 |
| March 31, 2026 | ¥54.28 |
| February 27, 2026 | ¥46.65 |
| January 30, 2026 | ¥50.68 |
| December 31, 2025 | ¥51.32 |
| November 28, 2025 | ¥59.82 |
| November 20, 2025 | ¥56.68 |
At a glance
The company
Researches, develops, manufactures and sells pharmaceutical products for anesthesia, endocrine, cardiovascular, psychiatric, oncology and other therapeutic areas in China
Latest results
Quarter to September 30, 2026 · EPS ¥0.46 (estimate ¥0.38)
Next event
TickerLandia's take on Haisco Pharmaceutical Group
- Pricier than usual relative to earnings: P/E on the latest fiscal year 228 vs a median of 58 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 44 vs 42 (+6%) in a group of 8.
- Strong point: Earnings stability (88/100 in its group). Weak point: Financial strength (27/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−35.07% from the 52-week high
Analysts · 4 analysts
Average target¥88.47+68.57% vs. price
Buy 4 · Hold 0 · Sell 0
TickerLandia Fingerprint: Haisco Pharmaceutical Group
Compared with similar companies: very high earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricehigh68
How much it costs relative to what it produces.
Metric Value Position in group Price/book 9.99 77 Forward P/E 38.0 76 P/E (trailing 12 months) 44.1 60 Price/sales 9.88 55 EV/EBITDA 37.9 72 Profitabilityhigh66
How much it earns on revenue and capital.
Metric Value Position in group Net margin 21.5% 66 Operating margin 21.1% 55 ROA 9.8% 78 Gross margin 77.3% 55 ROE 25.6% 78 Earnings stabilityvery high88
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.2% 92 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthhigh66
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +44.30% 72 Earnings growth (year over year) +203.20% 92 Average revenue growth (3 years) +13.32% 36 Financial strengthlow27
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.38 29 Current ratio 1.94 16 Interest coverage 6.14 42 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.11 22 Dividendhigh67
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.5% 69 Payout ratio 66.6% 81 Consecutive dividend years 3 years 50 Market momentumaverage42
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average −9.18% 47 1-year return −7.41% 37 Riskaverage54
How much the price swings.
Metric Value Position in group Volatility (60 days) 41.1% 59 Maximum drawdown (12 months) 33.7% 49
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Haisco Pharmaceutical Group is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Haisco Pharmaceutical Group's P/E today is 228.2, above the median of its last 10 fiscal years (57.7; between 29.7 and 223.1 from 2016 to 2025). Haisco Pharmaceutical Group's P/E (trailing 12 months): 44.1, +6% against the median of a group of 8 similar companies (41.7).
Compared with 8 similar companies
| Metric | Haisco Pharmaceutical Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 44.1 | Middle | |
| Forward P/E | 38.0 | Middle | |
| Operating margin | 21.1% | Middle | |
| ROE | 25.6% | High | |
| Debt/equity | 0.38 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Haisco Pharmaceutical Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥1.87B
Latest quarter · Q3 2026
Net income
¥525.25M
Latest quarter · Q3 2026
Quarterly net margin
28.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥59.87B
- P/E
- 44.1
- EPS
- ¥1.19
- Volume
- 3.74M
- Daily trading
- €32.45M
- Dividend yield
- 1.51%
- Last ex-dividend on September 4, 2026
How Haisco Pharmaceutical Group is changing
All resultsRevenue grew 5.7% a year on average over the last 5 years
Less cash than profit: free cash flow equal to 54% of net income
Shares outstanding up 4.6% in 5 years
Returns
Haisco Pharmaceutical Group returns with dividends
¥1,000 invested in Haisco Pharmaceutical Group 5 years ago, on November 22, 2021, would be worth ¥2,820 today with dividends reinvested: +182.04% in total, +23.08% per year. On price alone it would be ¥2,704 (+170.38%).
| Period | Haisco Pharmaceutical Group | ¥1,000 becomes |
|---|---|---|
| 1 month | −11.95% | ¥881 |
| 6 months | +0.54% | ¥1,005 |
| Year to date | +2.26% | ¥1,023 |
| 1 year | −6.23% | ¥938 |
| 3 years | +127.72% | ¥2,277 |
| 5 years | +182.04% | ¥2,820 |
| 10 years | +235.18% | ¥3,352 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Haisco Pharmaceutical Group: technical analysis
Haisco Pharmaceutical Group shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 33.7% below its all-time closing high (¥79.19, July 16, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 33
- Between 30 and 70
- vs 200-session average
- −9.18%
Active signals
Close below the low of the previous 55 sessions.
The last session opened more than 3% above the previous close.
Support and resistance
Price areas where Haisco Pharmaceutical Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance¥61.96+18.05%8 touches, last on November 5, 2026
- Resistance¥58.66+11.78%3 touches, last on August 3, 2026
- Resistance¥54.66+4.16%5 touches, last on November 2, 2026
- Last price¥52.48
- Support¥52.35−0.25%3 touches, last on April 9, 2026
- Support¥50.53−3.73%4 touches, last on June 12, 2026
- Support¥45.99−12.37%2 touches, last on June 9, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 41.1%
- Largest fall in the last year
- −33.73%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Haisco Pharmaceutical Group: seasonality
Average monthly price change over 15 years
Over the last 15 years, the strongest month for Haisco Pharmaceutical Group has been March: +7.70% on average, positive in 9 years out of 15. The weakest has been December: −3.09% on average, positive in 4 years out of 14. November, the current month, has been positive in 6 years out of 14 (−2.54% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.66% | −1.28% | 6 of 14 |
| February | +3.05% | +2.61% | 9 of 15 |
| March | +7.70% | +13.23% | 9 of 15 |
| April | +1.42% | +0.80% | 9 of 15 |
| May | +5.42% | +3.94% | 10 of 15 |
| June | +3.44% | −0.50% | 7 of 15 |
| July | +1.99% | −2.03% | 7 of 15 |
| August | +3.00% | +6.18% | 10 of 15 |
| September | −0.27% | +0.97% | 8 of 15 |
| October | +1.37% | +3.08% | 9 of 15 |
| November | −2.54% | −1.77% | 6 of 14 |
| December | −3.09% | −4.37% | 4 of 14 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Haisco Pharmaceutical Group and its competitors
China is the main market for Haisco Pharmaceutical Group Co., Ltd., which researches, develops, manufactures and sells pharmaceutical products there. Its portfolio covers anesthesia and analgesic drugs, endocrine system treatments, enteral and parenteral nutrition products, cardiovascular, psychiatric, tumor-related and digestive liver disease medicines, and treatments for other diseases. The group also works with Eli Lilly on medicines spanning several therapeutic fields, and it changed its name from Xizang Haisco Pharmaceutical Group in March 2016.
- Headquarters
- Shannan, China
- Employees
- 5,597
- Founded
- 2000
- Chief executive
- Pangke Yan
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Haisco Pharmaceutical Group002653 | $8.97B | 21.1% | 44.1 | +0.54% |
| ALTEOGEN196170 | $9.05B | 47.2% | 97.1 | −36.93% |
| Genscript Biotech1548 | $8.77B | 14.9% | — | +112.07% |
| Pharmaron Beijing300759 | $10.59B | 14.0% | 39.3 | +44.36% |
| Sino Biopharmaceutical1177 | $11.65B | 28.2% | 34.2 | −1.26% |
| Akeso9926 | $6.81B | -30.7% | — | −50.70% |
Same industry or related industries, similar size. Compare Haisco Pharmaceutical Group with its competitors · Full profile
More on Haisco Pharmaceutical Group
- Haisco Pharmaceutical Group revenue and financials
- Haisco Pharmaceutical Group dividend and valuation
- Haisco Pharmaceutical Group stock return
- Haisco Pharmaceutical Group employees, headquarters and business
